Search

Cancer biologist Hans-Guido Wendel pursues both disease-centered and basic discovery research. The disease focus is on lymphocyte malignancies and the basic science arm of the lab explores fundamental mechanisms that control aberrant mRNA translation programs in cancer. Work in these two research areas frequently intersects in surprising ways.

… Our goal is to develop new cancer therapeutics and we are curious to identify biological vulnerabilities in cancer cells that provide opportunities for attack. Our research explores the molecular and cellular changes that drive cancer cells and ways to create new types of therapeutics including small

The Goldberg laboratory focuses on structural and biochemical characterization of intracellular vesicle transport.

… Our research group studies the mechanisms of protein trafficking and quality control at the endoplasmic reticulum (ER) in mammalian cells. A major focus of research is on the COPII protein machinery responsible for synthesis of ER-derived transport vesicles. We are exploring the mechanisms utilized by

My research is focused on cellular and molecular mechanisms that control the differentiation, maintenance, and physiological functions of macrophages and monocytes and their roles in tissue homeostasis and disease processes.

… Over the past ten years, we have investigated the developmental origin and homeostasis of macrophages and the related cell types monocytes and dendritic cells. These cells play a major role in diverse types of cancer and can either restrain or promote cancer progression and metastasis. The Geissmann

The Hadjantonakis laboratory studies pluripotency and cell fate specification, tissue patterning and morphogenesis, in mammalian embryos and stem cell-derived embryo models.

… Cancer is a condition arising when cells undergo an identity crisis.  Understanding of how cells control their identity, and how they assemble into tissues with normal organization and function during embryonic development provides the essential blueprint for gaining insights into the fundamental biological

Cancer biologist Andrea Ventura studies non-coding RNAs in cancer and development

… One of the most exciting discoveries of the last two decades has been the identification of a large number of non-coding RNAs and the realization that they play essential roles in mammalian development and in diseases. Their study and the characterization of their contribution to the pathogenesis of

We leverage large-scale unbiased profiling including genomics, transcriptomics, proteomics to identify candidate oncogenes and proteins that are pathogenetically relevant in lymphoma.

… Kojo S. Elenitoba-Johnson is the Chair of the Department of Pathology and Laboratory Medicine and a physician-scientist. Dr. Elenitoba-Johnson’s research focuses on the role of genomic and proteomic alterations in the pathogenesis of lymphomas. Dr. Megan S. Lim is the Director of the Lymphoma Translational

Physician-scientist Babak Mehrara studies the regulation of lymphatic regeneration after surgery and development of lymphedema.

… Our research group focuses on the lymphatic system in three different pathological settings: lymphedema, obesity, and cancer. Chronic lymphedema is a morbid disease condition without any cure. Our first goal is to uncover the pathology behind development and progression of cancer-related secondary lymphedema

Physician-scientist Karlo Perica develops cell therapies to treat a wide variety of cancers, focusing on off-the-shelf approaches such as allogeneic CAR T cells and in vivo gene editing.

… The laboratory of Dr. Karlo Perica focuses on developing new Chimeric Antigen Receptor T cell and other cell therapies for cancer. We seek to make cell therapy more accessible and more effective by developing “off-the-shelf” approaches using allogeneic cell therapies and in vivo editing. Our research

Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.

… Our lab is focused on understanding the mechanism of disease recurrence, response to therapies and disease progression of upper tract urothelial cancer, a rare but aggressive disease. To interrogate molecular diversity of the disease, we employ genomics, transcriptomics, metabolomics and tumor immune

New roles for Notch signaling in the immune system.

… Dr. Maillard’s research focuses on the role of Notch signaling in hematopoiesis as well as in T and B cell development, differentiation and function. Through more than 15 years of research in the field, his laboratory discovered essential functions for Notch receptors and ligands in graft-versus-host